Physician profile
Kali Gray
NPI 1003439852
$3,063.39
in general payments reported to CMS, 2019-2025
26 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $116 · 2021: $286 · 2022: $659 · 2023: $490 · 2024: $490 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,944 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,944.07 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $537.41 | 2021-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $418.91 | 2023-2025 | |
| Novo Nordisk INC | $394.69 | 2022-2025 | Rybelsus, Ozempic |
| Vifor Pharma, INC. | $356.87 | 2020-2023 | Veltassa |
| Regeneron Healthcare Solutions, INC. | $238.41 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $163.34 | 2024-2025 | Ultomiris |
| Calliditas Therapeutics US INC. | $140.76 | 2023-2025 | Tarpeyo |
| Pulmonx Corporation | $134.51 | 2022 | |
| Akebia Therapeutics INC | $129.04 | 2021-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $96.23 | 2023-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $75.73 | 2025 | |
| Genzyme Corporation | $52.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.91 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $41.88 | 2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $34.82 | 2021-2023 | Velphoro, Korsuva |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $32.21 | 2025 | Gazyva |
| Mallinckrodt Hospital Products INC. | $24.67 | 2025 | Terlivaz |
| Scpharmaceuticals INC. | $20.42 | 2025 | |
| Glaxosmithkline, LLC. | $20.08 | 2025 | Benlysta |
| Amgen INC. | $18.12 | 2025 | Tavneos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.75 | 2023 | Xifaxan |
| Kyowa Kirin, INC. | $14.44 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.29 | 2025 | Brilinta |
| Pfizer INC. | $14.14 | 2022 | |
| Ani Pharmaceuticals, INC. | $13.66 | 2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $13.57 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kali Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.